Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 11.80% | 8.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.80% | 8.19% | |||
| Cost of Revenue | 16.30% | 2.77% | |||
| Gross Profit | 7.04% | 14.57% | |||
| SG&A Expenses | -2.60% | 12.90% | |||
| Depreciation & Amortization | 6.31% | -11.50% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.91% | 3.69% | |||
| Operating Income | 70.76% | 849.79% | |||
| Income Before Tax | 26.67% | 678.46% | |||
| Income Tax Expenses | -57.15% | 24.94% | |||
| Earnings from Continuing Operations | 49.11% | 330.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.11% | 330.74% | |||
| EBIT | 70.76% | 849.79% | |||
| EBITDA | 62.94% | -11.63% | |||
| EPS Basic | 50.55% | 331.52% | |||
| Normalized Basic EPS | 897.18% | -30.39% | |||
| EPS Diluted | 46.32% | 320.34% | |||
| Normalized Diluted EPS | 891.55% | -30.39% | |||
| Average Basic Shares Outstanding | -0.89% | -0.32% | |||
| Average Diluted Shares Outstanding | -0.94% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||